Barclays reaffirms its 'weight in line' recommendation on Dassault Systèmes, with a price target lowered from €40 to €37, assessing the competitive risk that Veeva's progress would imply for the life sciences software group's prospects.

The broker concludes that the risk of disruption to Dassault's Medidata division is not immediate, but warns that if Veeva were to take a larger share, Medidata might find it difficult to continue outperforming market growth.

Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.